Navigation Links
Anadys Pharmaceuticals Updates Its Presentation Date at the Stifel Nicolaus Healthcare Conference
Date:9/6/2011

l in nature constitute "forward-looking statements."  Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements.  For example, the results of preclinical and early clinical studies may not be predictive of future results, and Anadys cannot provide any assurances that setrobuvir (ANA598) or ANA773 will not have unforeseen safety issues, will have favorable results in ongoing or future clinical trials or will receive regulatory approval. In addition, Anadys' results may be affected by competition from other biotechnology and pharmaceutical companies, its effectiveness at managing its financial resources, its ability to enter into transactions around its product candidates, its ability to successfully develop and market products, difficulties or delays in its non-clinical studies or clinical trials, difficulties or delays in manufacturing its clinical trials materials, the scope and validity of patent protection for its products, regulatory developments and its ability to obtain additional funding to support its operations.  Risk factors that may cause actual results to differ are more fully discussed in Anadys' SEC filings, including Anadys' Form 10-Q for the quarter ended June 30, 2011.  All forward-looking statements are qualified in their entirety by this cautionary statement.  Anadys is providing this information as of this date and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.


'/>"/>
SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Anadys Pharmaceuticals to Report Third Quarter 2008 Financial Results
2. Anadys Pharmaceuticals to Present at BIOCOM Investor Conference 2008
3. Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights
4. Anadys Pharmaceuticals Commences Dosing ANA773 in Hepatitis C Patients
5. Anadys Pharmaceuticals to Present at Rodman & Renshaw Annual Global Investment Conference
6. Anadys Pharmaceuticals to Present at the Needham Focus on Infectious Disease Conference
7. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
8. Anadys Pharmaceuticals to Present at Future Leaders in the Biotech Industry
9. Anadys Pharmaceuticals to Report First Quarter 2009 Financial Results
10. Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights
11. Anadys Pharmaceuticals, Inc. Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 24, 2014  Vermillion, Inc. (Nasdaq: ... gynecologic disease, announced today that the Company closed ... Oracle Investment Management, Jack W. Schuler , ... proceeds were $10.5 million, before offering expenses.  The ...
(Date:12/24/2014)... GMO corn cases filed across the United States, ... of being consolidated in a Kansas federal court for pretrial ... 162 Corn Litigation, MDL No. 2591 in the U.S. District ... Syngenta GMO corn multidistrict litigation (MDL) has been handed over ...
(Date:12/24/2014)... 23, 2014 On Friday, December 19, ... Omnibus and Continuing Resolution Appropriations Act of 2015, which ... to receive funding through the Congressionally Directed Medical Research ... The Hydrocephalus Association (HA), working in conjunction with its ...
(Date:12/24/2014)... (PRWEB) December 23, 2014 Nashville Fertility Center ... treasurer for the American Society for Reproductive Medicine (ASRM), a ... reproductive medicine. In his new role as treasurer, Dr. ... will have a voice in furthering the mission of ASRM. ...
Breaking Biology Technology:Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 2Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 3
... Bill of Rights are right about one thing: Wisconsin needs ... and local government. Our tax system hampers economic growth and ... ,But the opponents of TABOR are right about one thing, ... put at risk our economic growth and threaten our quality ...
... with the product managers at Palm and got a peek at ... be an entry-level digital organizer for the masses of people who ... simple product that delivered real value. After listening to the briefing ... close to the product marketing manager and said, "You're going to ...
... MobilePro Corp. announced today the company has ... , a Janesville-based Internet services provider. The deal is ... in annualized revenue and to be accretive to MobilePros ... of definitive agreements and customary closing conditions, is expected ...
Cached Biology Technology:Tax consumption over production to reform Wisconsins tax system 2Tax consumption over production to reform Wisconsins tax system 3The Palm to "de-Zire" 2The Palm to "de-Zire" 3
(Date:12/17/2014)... Research and Markets ( http://www.researchandmarkets.com/research/9zq33j/global_chemical ) has ... Market 2015-2019" report to their offering. ... trend upcoming in this market is the increasing demand ... in recording of patient data for quick and correct ...
(Date:12/11/2014)... DUBLIN , Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition ... 2015-2019"  report to their offering. One ... technology. With continuous advances in technology, it is important ...
(Date:12/11/2014)... Dec. 10, 2014  Data Sciences International (DSI), the ... a new series of digital telemetry implants to ... M series, part of the PhysioTel™ Digital platform, ... possible physiologic data when incorporating functional endpoints into ...
Breaking Biology News(10 mins):Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2New telemetry implants expected to change how large animal toxicology studies are conducted 2
... 15th September, 2008: New research published today at the ... Mineral Research (ASBMR), Montral, Canada, reveals that less than ... claiming to take both calcium and vitamin D supplementation ... managing osteoporosis can be achieved with combination therapy of ...
... More than 30 years ago, Alfred Knudson Jr., M.D., ... that a person must lose both their paternal and ... called tumor-suppressor genes, in order to develop cancer. This ... globe in their quest for tumor suppressor genes. Now ...
... Ariz. Sept. 14, 2008 Investigators at the ... and less expensive way for scientists to find which ... unlike what shoppers find in grocery stores, TGen researchers ... 3-billion-base human genetic code, making it easier for scientists ...
Cached Biology News:Majority of osteoporosis patients not receiving calcium and vitamin D with treatment 2Majority of osteoporosis patients not receiving calcium and vitamin D with treatment 3'1-hit' event provides new opportunity for colon cancer prevention, say Fox Chase researchers 2TGen investigators devise faster, cheaper way of analyzing the human genome 2
... histochemically detect specific senescence ... in cultured cells and ... marker is only present ... found in presenescent/quiescent/immortal cells. ...
TAR DNA binding protein...
... Star strains are high-performance ... improved protein yield in ... (Figure 1). Because the ... mRNA more rapidly than ...
...
Biology Products: